48,466
edits
Difference between revisions of "SMARCA4-deficient non-small cell carcinoma of the lung"
Jump to navigation
Jump to search
SMARCA4-deficient non-small cell carcinoma of the lung (view source)
Revision as of 15:57, 31 October 2023
, 15:57, 31 October 2023no edit summary
(→IHC) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
*~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue = | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref> | *~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue = | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref> | ||
*May represent ''or'' overlap with what is known as ''hepatoid adenocarcinoma of the lung''.{{fact}} | *May represent ''or'' overlap with what is known as ''hepatoid adenocarcinoma of the lung''.{{fact}} | ||
*The main differential diagnosis is ''metastatic adenocarcinoma''. | |||
==IHC== | ==IHC== | ||
Features:<ref name=pmid28555282/> | Features:<ref name=pmid28555282/> | ||
*CK7 +ve. | *CK7 +ve. | ||
*TTF-1 -ve. | *[[TTF-1]] -ve. | ||
*HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/> | *HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/> | ||
*SMARCA4 -ve. | *SMARCA4 -ve. | ||
*Napsin A -ve (1/28 +ve).<ref>{{cite journal |authors=Sayeda S, Naqvi A, Begum H, Finley C, Coschi C, Juergens R, Bonert M. |title=34th European Congress of Pathology - Abstracts (''Prevalence of TTF-1 negative lung adenocarcinoma on lung core biopsy with EGFR, ALK and PD-L1 status'') |journal=Virchows Arch |volume=481 |issue=Suppl 1 |pages=1–364 |date=August 2022 |pmid=35972647 |pmc=9379246 |doi=10.1007/s00428-022-03379-4 |url=}}</ref> | |||
Note: | Note: | ||
| Line 30: | Line 32: | ||
==See also== | ==See also== | ||
*[[Lung adenocarcinoma]]. | *[[Lung adenocarcinoma]]. | ||
*[[SMARCB1]] (INI-1). | |||
==References== | ==References== | ||